Advertisement

Pharmacy World and Science

, Volume 28, Issue 4, pp 215–221 | Cite as

Are higher vancomycin doses needed in venticle-external shunted patients?

  • Meritxell Pujal
  • Dolors SoyEmail author
  • Carles Codina
  • Josep Ribas
ORIGINAL PAPER

Abstract

Objective

Hydrocephalus is usually resolved by diverting cerebrospinal fluid through a surgically implanted intra-ventricular catheter (shunt). The aim of this study was to characterize vancomycin pharmacokinetic (PK) parameters and optimal dosage in shunted patients under vancomycin treatment.

Setting

Intensive Care and Neurosurgical Units. University Hospital.

Methods

Retrospective data of vancomycin blood concentrations, demographics and biochemical parameters, from a Therapeutic Drug Monitoring (TDM) program, in ventricle-external shunted patients (Group A) and controls (Group B) were collected. In all subjects, several blood samples at steady state conditions were drawn. Individual PK parameters such as drug clearance (CL) and volume of distribution (V) were estimated by using an one-compartmental PK model and later, dosage regimens were individually adjusted by Bayesian analysis. The obtained CL and V mean ± standard deviation were compared between both groups (A versus B). Vancomycin dosage regimens between both groups were also compared.

Main outcome measures

Patients demographics, clinical records, creatinine clearance by Cockcroft-Gault, vancomycin blood levels, vancomycin pK parameters and optimal initial IV vancomycin dosage.

Results

Forty-five patients were included in the study: 15 patients in group A and 30 subjects in group B. Significant differences between CLA and CLB means were observed, while not between VA and VB. In shunted patients, the required vancomycin daily dose to reach target concentrations was significantly higher than the dose needed in the control group (49.25 ± 12.28 mg/kg/day vs. 31.74 ± 6.70 mg/kg/day; P < 0.0005).

Conclusions

Greater vancomycin clearance was found in our shunted patients, thus they required higher vancomycin daily doses compared to the control group. Consequently, vancomycin TDM in shunted patients should be advisable in order to guarantee antibiotic blood concentrations within the recommended therapeutic range.

Keywords

Hydrocephalus Optimal dosage Pharmacokinetic parameters Therapeutic Drug Monitoring TDM Vancomycin Ventricle-external shunt 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

The authors would like to thank Núria Miserachs, Laura Gratacós, Patricia Domínguez and Marina Rovira at the Pharmacy Service of Hospital Clínic de Barcelona for their collaboration in the vancomycin TDM process.

References

  1. 1.
    Farreras P, Rozman C. Medicina interna, vol II, XIV Ed. Harcourt, S.A., Madrid. ISBN 84-8174-359-3. 2000;1645, 1709–10Google Scholar
  2. 2.
    Ammirati M, Raimondi AJ. Cerebrospinal fluid shunt infections in children. A study on the relationship between the etiology of hydrocephalus, age at the time of shunt placement and infection rate. Child's Nerv Sys 1987;3:106–9CrossRefGoogle Scholar
  3. 3.
    Bayston R. Hydrocephalus shunt infections. J Antimicrob Chemother 1994; 34(Suppl. A):75–84PubMedGoogle Scholar
  4. 4.
    Choux M, Genitori L, Lang D, Lena G. Shunt implantation: reducing the incidence of shunt infection. J Neurosurg 1992; 77:875–80PubMedCrossRefGoogle Scholar
  5. 5.
    Ellenbogen RG, Goldmann DA, Winston KR. Group B Streptococcal infections of the central nervous system in infants with myelomeningocele. Surg Neurol 1988;29:237–42PubMedCrossRefGoogle Scholar
  6. 6.
    Vinchon M, Vallee L, Prin L, Desreumaux P, Dhellemmes P. Cerebro-spinal fluid eosinophilia in shunt infections. Neuropediatrics 1992;23:235–40PubMedGoogle Scholar
  7. 7.
    Bafeltowska JJ, Buszman E, Mandat KM, Hawranek JK. Therapeutic vancomycin monitoring in children with hydrocephalus during treatment of shunt infections. Surg Neurol 2004 Aug;62(2):142PubMedCrossRefGoogle Scholar
  8. 8.
    Bourgeois M, Sainte-Rose C, Cinalli G, Maixner W, Malucci C, Zera M, et al. Epilepsy in children with shunted hydrocephalus. J Neurosurg 1999 Feb;90(2):274–81PubMedCrossRefGoogle Scholar
  9. 9.
    Bennett DR, editor. Drug evaluations subscription. Chicago, IL: American Medical Association, Winter 1992Google Scholar
  10. 10.
    Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharmaceut 1981; 9:503–12CrossRefGoogle Scholar
  11. 11.
    Fernandez de Gatta MM, Fruns I, Calvo MV, Lanao JM, Dominguez-Gil A. Influence of pharmacokinetic model on vancomycin peak concentration targets. Ther Drug Monit 1996 Apr;18(2):145–8PubMedCrossRefGoogle Scholar
  12. 12.
    Odenholt-Tornqvist I, Löwdin E, Cars C. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother. 1992 sep;36(9):1852–8PubMedGoogle Scholar
  13. 13.
    Soy D, Badia JR, Torres A. Antibiotic Dosage Regimens in Respiratory Tract Infections in the pharmacokinetic/pharmacodynamic era. Curr Respiratory Med Rev 2006;2:89–97CrossRefGoogle Scholar
  14. 14.
    Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ, Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987 Mar;31(3):393–7Google Scholar
  15. 15.
    Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimes: one- versus two-compartment Bayesian models. Ther Drug Monit 1989; 11:450–4Google Scholar
  16. 16.
    Albrecht LM, Rybak MJ, Boike SC, Pancorbo S. Comparison of serum sampling methods for determining vancomycin dosage regimes. Ther Drug Monit 1988;10:85–90Google Scholar
  17. 17.
    Walson PD. Therapeutic drug monitoring in special populations. Clin Chem 1998;44(2):415–9Google Scholar
  18. 18.
    Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Spokane, Applied Therapeutics, Inc. 1992Google Scholar
  19. 19.
    Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993 May;24(5):362–79PubMedCrossRefGoogle Scholar
  20. 20.
    DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004 Sep;58(3):259–68PubMedCrossRefGoogle Scholar
  21. 21.
    Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988 Jun;32(6):848–52PubMedGoogle Scholar
  22. 22.
    PachoreK RE, Wood F. Vancomycin half-life in a patient with hepatic and renal dysfunction. Clin Pharm 1991; 10:297–300PubMedGoogle Scholar
  23. 23.
    Soto J, Alsar MJ, Sacristan JA. Initial dosage of vancomycin in neutropenic hematologic patients. Sangre (Barc) 1992 Jun; 37(3):181–4Google Scholar
  24. 24.
    Tomás R, Soy D, García-Peláez M, Cardenete J, Quintana E, Mangues MA. High dose requirements of vancomycin in multiple trauma adult patients in intensive care units [Abstract]. Pharm World Sci 2000;22(1):28 [A47]Google Scholar
  25. 25.
    Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000 Mar;45(3):329–35PubMedCrossRefGoogle Scholar
  26. 26.
    Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990 May;34(5):792–5PubMedGoogle Scholar
  27. 27.
    Conil JM, Favarel H, Laguerre J, Brouchet A, Chabanon G, Cazal L, et al. Continuous administration of vancomycin in patients with severe burns. Presse Med 1994 Nov 5; 23(34):1554–8PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Meritxell Pujal
    • 1
  • Dolors Soy
    • 1
    Email author
  • Carles Codina
    • 1
  • Josep Ribas
    • 1
  1. 1.Pharmacy Service (UASP), Hospital Clínic de BarcelonaUniversity of BarcelonaBarcelonaSpain

Personalised recommendations